Your browser doesn't support javascript.
loading
Unlocking the 'ova'-coming power: immunotherapy's role in shaping the future of ovarian cancer treatment.
Haines, Nathan A; Fowler, Mia G; Zeh, Benjamin G; Kriete, Carter B; Bai, Qian; Wakefield, Mark R; Fang, Yujiang.
Afiliación
  • Haines NA; Department of Microbiology, Immunology & Pathology, Des Moines University College of Osteopathic Medicine, 8025, Grand Ave, West Des Moines, IA, 50266, USA.
  • Fowler MG; Department of Surgery, University of Missouri School of Medicine, Columbia, MO, 65212, USA.
  • Zeh BG; Department of Surgery, University of Missouri School of Medicine, Columbia, MO, 65212, USA.
  • Kriete CB; Department of Microbiology, Immunology & Pathology, Des Moines University College of Osteopathic Medicine, 8025, Grand Ave, West Des Moines, IA, 50266, USA.
  • Bai Q; Department of Surgery, University of Missouri School of Medicine, Columbia, MO, 65212, USA.
  • Wakefield MR; Department of Surgery, University of Missouri School of Medicine, Columbia, MO, 65212, USA.
  • Fang Y; Department of Surgery, University of Missouri School of Medicine, Columbia, MO, 65212, USA.
Med Oncol ; 41(3): 67, 2024 Jan 29.
Article en En | MEDLINE | ID: mdl-38286890
ABSTRACT
Ovarian cancer is a prominent cancer worldwide with a relatively low survival rate for women diagnosed. Many individuals are diagnosed in the late stage of the disease and are prescribed a wide variety of treatment options. Current treatment options are primarily a combination of surgery and chemotherapy as well as a new but promising treatment involving immunotherapy. Nevertheless, contemporary therapeutic modalities exhibit a discernible lag in advancement when compared with the strides achieved in recent years in the context of other malignancies. Moreover, many surgery and chemotherapy options have a high risk for recurrence due to the late-stage diagnosis. Therefore, there is a necessity to further treatment options. There have been many new advancements in the field of immunotherapy. Immunotherapy has been approved for 16 various types of cancers and has shown significant treatment potential in many other cancers as well. Researchers have also found many promising outlooks for immunotherapy as a treatment for ovarian cancer. This review summarizes many of the new advancements in immunotherapy treatment options and could potentially offer valuable insights to gynecologists aimed at enhancing the efficacy of their treatment approaches for patients diagnosed with ovarian cancer.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas Idioma: En Revista: Med Oncol Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas Idioma: En Revista: Med Oncol Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article